Reuters logo
BRIEF-Innate Pharma acquires anti-C5aR from Novo Nordisk
June 2, 2017 / 8:37 PM / 7 months ago

BRIEF-Innate Pharma acquires anti-C5aR from Novo Nordisk

June 2 (Reuters) - Innate Pharma Sa

* Innate Pharma acquires anti-C5aR, a first-in-class clinical-stage antibody, from Novo Nordisk A/S

* Says Innate Pharma intends to start clinical trials with anti-C5aR (iph5401) in oncology in 2018

* Says acquisition is part of a transaction in which Novo Nordisk A/S will increase its equity stake in Innate Pharma

* Innate Pharma - terms provide for a total upfront payment of EUR 40M, of which EUR 37.2M will be paid in new Innate Pharma shares and EUR 2.8M in cash

* Says Novo Nordisk A/S will be eligible for EUR 370M in development, regulatory and sales milestone payments

* Says Novo Nordisk A/S will also be eligible for double digit royalties on net sales. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below